ARNOLD L. ORONSKY, PH.D. - Corporate Board Profile

DYNAVAX TECHNOLOGIES CORP

Filing Date	Source Excerpt
2012-04-25	Arnold L. Oronsky, Ph.D. 72 Chairperson of the Board ... The Audit Committee is composed of three directors: Dr. Gilbert (Chairperson), Dr. Oronsky and Ms. Phillips ... The following table shows for the fiscal year ended December 31, 2011 certain information with respect to the compensation of all non-employee directors of the Company: Arnold L. Oronsky, Ph.D. $63,500 $22,846 $86,346
2013-04-29	Arnold L. Oronsky, Ph.D. 73 Chairperson of the Board ... The following table shows for the fiscal year ended December 31, 2012, certain information with respect to the compensation of all non-employee directors of the Company: Arnold L. Oronsky, Ph.D. Fees Earned or Paid in Cash $72,500 Options and Awards Granted $183,419 Total $255,919 ... The Audit Committee is composed of three directors: Dr. Gilbert (Chairperson), Dr. Oronsky and Ms. Phillips.
2014-04-28	Arnold L. Oronsky, Ph.D. 74 Chairperson of the Board ... The Audit Committee is composed of three directors: Dr. Gilbert (Chairperson), Dr. Oronsky and Ms. Phillips ... The following table shows for the fiscal year ended December 31, 2013, certain information with respect to the compensation of all non-employee directors of the Company: Arnold L. Oronsky, Ph.D. Fees Earned or Paid in Cash $43,000 Options and Awards Granted $44,625 Total $87,625
2015-04-21	Arnold L. Oronsky, Ph.D. 75 Chairperson of the Board ... Dr. Oronsky has been a member of our Board since November 1996 and became Chairman in February 2006. ... The Audit Committee for 2014 was composed of three directors: Dr. Gilbert (Chairperson), Dr. Oronsky and Ms. Phillips. ... The following table shows for the fiscal year ended December 31, 2014, certain information with respect to the compensation of all non-employee directors of the Company: Arnold L. Oronsky, Ph.D. $72,500 fees earned or paid in cash, $22,901 options and awards, total $95,401.
2016-04-22	Arnold L. Oronsky, Ph.D. 75 Chairperson of the Board ... Our Board is currently chaired by Dr. Oronsky ... The Audit Committee for 2015 was comprised of three directors: Dr. Gilbert (Chairperson), Dr. Oronsky and Ms. Phillips ... The following table shows for the fiscal year ended December 31, 2015, certain information with respect to the compensation of all non-employee directors of the Company: Arnold L. Oronsky, Ph.D. $72,500 Fees Earned or Paid in Cash, $294,558 Option Awards, $367,058 Total.
2017-04-21	Arnold L. Oronsky, Ph.D. 76 Chairperson of the Board ... Our Board is currently chaired by Dr. Oronsky ... Audit Committee for 2016 was comprised of three directors: Ms. Brege (Chairperson), Dr. Oronsky and Ms. Phillips ... The following table shows for the fiscal year ended December 31, 2016, certain information with respect to the compensation of all non-employee directors of the Company: Arnold L. Oronsky, Ph.D. $72,500 Fees Earned or Paid in Cash, $70,692 Option Awards, $143,192 Total.
2017-07-10	Arnold L. Oronsky, Ph.D., Director
2018-04-20	Arnold L. Oronsky, Ph.D. 77 Chairperson of the Board ... The Audit Committee for 2017 was comprised of three directors: Ms. Brege (Chairperson), Dr. Oronsky and Ms. Phillips ... The following table shows for the fiscal year ended December 31, 2017, certain information with respect to the compensation of all non-employee directors of the Company: Arnold L. Oronsky, Ph.D. $72,500 $29,203 $101,703
2019-04-22	Our Board presently has eight members. There are three directors in the class whose term of office expires in 2019: Dennis A. Carson, M.D., Eddie Gray, and Laura Brege, each of whom is a nominee for director and currently a director of the Company. Dr. Carson, Mr. Gray and Ms. Brege were previously elected by the stockholders in 2016. If each nominee is elected at the Annual Meeting, each of these nominees will serve until the 2022 Annual Meeting and until his or her successor is elected and has qualified, or, if sooner, until the director's death, resignation or removal. We have a policy encouraging our directors' attendance at our annual meetings. There were six directors in attendance at our 2018 Annual Meeting. Directors are elected by a plurality of the votes of the holders of shares present in person or represented by proxy and entitled to vote on the election of directors. The three nominees receiving the highest number of affirmative votes will be elected. Shares represented by executed proxies will be voted, if authority to do so is not withheld, for the election of the nominees named below. Although the election of directors at the Annual Meeting is uncontested and directors are elected by a plurality of votes cast, and we therefore anticipate that each of the named nominees for director will be elected at the Annual Meeting, under our Corporate Governance Guidelines, any nominee for director is required to submit an offer of resignation for consideration by the Nominating and Corporate Governance Committee if such nominee for director (in an uncontested election) receives a greater number of "Withhold" votes than "For" votes. In such case, the Nominating and Corporate Governance Committee will then consider all of the relevant facts and circumstances and recommend to the Board the action to be taken with respect to such offer of resignation. For more information on this policy see the section entitled "Corporate Governance." If any nominee becomes unavailable for election as a result of an unexpected occurrence, your shares will be voted for the election of a substitute nominee proposed by our Board. Each person nominated for election has agreed to serve if elected. Our Board has no reason to believe that any nominee will be unable to serve. Our Board has three standing committees: an Audit Committee, a Compensation Committee and a Nominating and Governance Committee. The following table provides membership and meeting information for fiscal year 2018 for each of the Board committees: Name Audit Compensation Nominating Arnold L. Oronsky, Ph.D. X ... The following table shows for the fiscal year ended December 31, 2018, certain information with respect to the compensation of all non-employee directors of the Company: Name Fees Earned or Paid in Cash Option Awards Total Arnold L. Oronsky, Ph.D. $ 75,000 $ 156,767 $ 231,767
2020-04-17	Arnold L. Oronsky, Ph.D. Dr. Oronsky has been a member of our Board since November 1996. Dr. Oronsky has been a managing director with InterWest Partners, a venture capital firm, since 2009. Prior to joining InterWest Partners in 1994, Dr. Oronsky was Vice President of Discovery Research for the Lederle Laboratories division of American Cyanamid, a pharmaceutical company. From 1973 until 1976, Dr. Oronsky was head of the inflammation, allergy and immunology research program at Ciba-Geigy Pharmaceutical Company. Dr. Oronsky also serves as a senior lecturer in the Department of Medicine at The Johns Hopkins Medical School. Dr. Oronsky has won numerous grants and awards and has published over 125 scientific articles. Dr. Oronsky currently serves on the board of directors of KalVista Pharmaceuticals, Inc., a publicly traded biopharmaceutical company.Dr. Oronsky also served on the board of directors of MacroGenics, Inc., a biopharmaceutical company, from 2000 to 2014, Applied Genetic Technologies Corporation, a biotechnology company, from November 2003 until August 2017, and Tesaro, Inc., an oncology-focused biopharmaceutical company from June 2011 until May 2018. He received his Ph.D. from Columbia University, College of Physicians and Surgeons and his A.B. from New York University. The Board believes that Dr. Oronsky’s significant experience in growing and developing life sciences companies, particularly in the immunology area, provides significant leadership and insights for the Board in defining the strategy of the Company and qualifies him to serve as a director.